Actively Recruiting
Survey of Intravenous Recombinant ADAMTS13 Treatment in People with Congenital Thrombotic Thrombocytopenic Purpura
Led by Takeda · Updated on 2025-10-07
40
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying recombinant ADAMTS13, a treatment given by intravenous injection, for people with congenital thrombotic thrombocytopenic purpura cTTP in Japan. The main goal is to monitor side effects and see if this treatment helps prevent or improve cTTP. The study is observational, meaning the sponsor will not control how participants are treated but will guide how clinics record information. Participants will receive recombinant ADAMTS13 according to their clinics usual care. The study will follow these participants for up to 18 months to observe their treatment experience. During this time, the treatment is given intravenously as part of standard medical practice. Throughout the study, doctors will check for any treatment-related side effects and measure changes in platelet count, ADAMTS13 activity, and ADAMTS13 inhibitor levels. The study will also track the number of TTP events during periodic replacement therapy. Participants health and treatment outcomes will be monitored carefully during the 18-month period.
CONDITIONS
Brief Title
A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
Research Team
T
Takeda Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
